The primary strategic areas of the Liverpool ECMC are pancreatic cancer and haemato-oncology, with expertise in cancer biology and pharmacology to develop novel biomarkers of efficacy, resistance and drug safety.
Other areas of focus supported by local expertise are breast cancer with brain metastases, hepatobiliary cancers, urological oncology, and uveal melanoma.
The aims of the Liverpool ECMC are to:
· facilitate the transition of new drugs/combinations from early to late phase clinical trials with integrated biomarker development and to develop stratified approaches to more effective use of existing drugs
· improve access and recruitment to early phase trials for cancer patients in Merseyside and Cheshire
· increase Liverpool Cancer Trials Unit led early phase trials
· partner with the ECMC Network to deliver ECMC trials in the region
The Liverpool ECMC is also a paediatric centre.
Organisations affiliated with the Liverpool ECMC: